198 related articles for article (PubMed ID: 18793829)
1. Blockade of dopamine D(3) receptors in frontal cortex, but not in sub-cortical structures, enhances social recognition in rats: similar actions of D(1) receptor agonists, but not of D(2) antagonists.
Loiseau F; Millan MJ
Eur Neuropsychopharmacol; 2009 Jan; 19(1):23-33. PubMed ID: 18793829
[TBL] [Abstract][Full Text] [Related]
2. S33084, a novel, potent, selective, and competitive antagonist at dopamine D(3)-receptors: I. Receptorial, electrophysiological and neurochemical profile compared with GR218,231 and L741,626.
Millan MJ; Gobert A; Newman-Tancredi A; Lejeune F; Cussac D; Rivet JM; Audinot V; Dubuffet T; Lavielle G
J Pharmacol Exp Ther; 2000 Jun; 293(3):1048-62. PubMed ID: 10869410
[TBL] [Abstract][Full Text] [Related]
3. Selective blockade of dopamine D(3) versus D(2) receptors enhances frontocortical cholinergic transmission and social memory in rats: a parallel neurochemical and behavioural analysis.
Millan MJ; Di Cara B; Dekeyne A; Panayi F; De Groote L; Sicard D; Cistarelli L; Billiras R; Gobert A
J Neurochem; 2007 Feb; 100(4):1047-61. PubMed ID: 17266737
[TBL] [Abstract][Full Text] [Related]
4. Selective blockade of dopamine D3 receptors enhances while D2 receptor antagonism impairs social novelty discrimination and novel object recognition in rats: a key role for the prefrontal cortex.
Watson DJ; Loiseau F; Ingallinesi M; Millan MJ; Marsden CA; Fone KC
Neuropsychopharmacology; 2012 Feb; 37(3):770-86. PubMed ID: 22030711
[TBL] [Abstract][Full Text] [Related]
5. Selective blockade of D(3) dopamine receptors enhances the anti-parkinsonian properties of ropinirole and levodopa in the MPTP-lesioned primate.
Silverdale MA; Nicholson SL; Ravenscroft P; Crossman AR; Millan MJ; Brotchie JM
Exp Neurol; 2004 Jul; 188(1):128-38. PubMed ID: 15191809
[TBL] [Abstract][Full Text] [Related]
6. Antidepressant-like properties of the anti-Parkinson agent, piribedil, in rodents: mediation by dopamine D2 receptors.
Brocco M; Dekeyne A; Papp M; Millan MJ
Behav Pharmacol; 2006 Nov; 17(7):559-72. PubMed ID: 17021388
[TBL] [Abstract][Full Text] [Related]
7. S33138 (N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1] benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenyl-acetamide), a preferential dopamine D3 versus D2 receptor antagonist and potential antipsychotic agent: III. Actions in models of therapeutic activity and induction of side effects.
Millan MJ; Loiseau F; Dekeyne A; Gobert A; Flik G; Cremers TI; Rivet JM; Sicard D; Billiras R; Brocco M
J Pharmacol Exp Ther; 2008 Mar; 324(3):1212-26. PubMed ID: 18096759
[TBL] [Abstract][Full Text] [Related]
8. S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: I. Cellular, electrophysiological, and neurochemical profile in comparison with ropinirole.
Millan MJ; Cussac D; Gobert A; Lejeune F; Rivet JM; Mannoury La Cour C; Newman-Tancredi A; Peglion JL
J Pharmacol Exp Ther; 2004 Jun; 309(3):903-20. PubMed ID: 14978194
[TBL] [Abstract][Full Text] [Related]
9. A 68930 and dihydrexidine inhibit locomotor activity and d-amphetamine-induced hyperactivity in rats: a role of inhibitory dopamine D(1/5) receptors in the prefrontal cortex?
Isacson R; Kull B; Wahlestedt C; Salmi P
Neuroscience; 2004; 124(1):33-42. PubMed ID: 14960337
[TBL] [Abstract][Full Text] [Related]
10. S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: II. Actions in rodent, primate, and cellular models of antiparkinsonian activity in comparison to ropinirole.
Millan MJ; Di Cara B; Hill M; Jackson M; Joyce JN; Brotchie J; McGuire S; Crossman A; Smith L; Jenner P; Gobert A; Peglion JL; Brocco M
J Pharmacol Exp Ther; 2004 Jun; 309(3):921-35. PubMed ID: 14978195
[TBL] [Abstract][Full Text] [Related]
11. S33138 [N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1]-benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenylacetamide], a preferential dopamine D3 versus D2 receptor antagonist and potential antipsychotic agent. II. A neurochemical, electrophysiological and behavioral characterization in vivo.
Millan MJ; Svenningsson P; Ashby CR; Hill M; Egeland M; Dekeyne A; Brocco M; Di Cara B; Lejeune F; Thomasson N; Munoz C; Mocaƫr E; Crossman A; Cistarelli L; Girardon S; Iob L; Veiga S; Gobert A
J Pharmacol Exp Ther; 2008 Feb; 324(2):600-11. PubMed ID: 18024787
[TBL] [Abstract][Full Text] [Related]
12. S33084, a novel, potent, selective, and competitive antagonist at dopamine D(3)-receptors: II. Functional and behavioral profile compared with GR218,231 and L741,626.
Millan MJ; Dekeyne A; Rivet JM; Dubuffet T; Lavielle G; Brocco M
J Pharmacol Exp Ther; 2000 Jun; 293(3):1063-73. PubMed ID: 10869411
[TBL] [Abstract][Full Text] [Related]
13. F15063, a potential antipsychotic with dopamine D(2)/D(3) receptor antagonist and 5-HT(1A) receptor agonist properties: influence on immediate-early gene expression in rat prefrontal cortex and striatum.
Bruins Slot LA; Lestienne F; Grevoz-Barret C; Newman-Tancredi A; Cussac D
Eur J Pharmacol; 2009 Oct; 620(1-3):27-35. PubMed ID: 19695244
[TBL] [Abstract][Full Text] [Related]
14. In vivo occupancy of dopamine D3 receptors by antagonists produces neurochemical and behavioral effects of potential relevance to attention-deficit-hyperactivity disorder.
Barth V; Need AB; Tzavara ET; Giros B; Overshiner C; Gleason SD; Wade M; Johansson AM; Perry K; Nomikos GG; Witkin JM
J Pharmacol Exp Ther; 2013 Feb; 344(2):501-10. PubMed ID: 23197772
[TBL] [Abstract][Full Text] [Related]
15. Dopaminergic modulation of risk-based decision making.
St Onge JR; Floresco SB
Neuropsychopharmacology; 2009 Feb; 34(3):681-97. PubMed ID: 18668030
[TBL] [Abstract][Full Text] [Related]
16. Effects of antipsychotics and selective D3 antagonists on PPI deficits induced by PD 128907 and apomorphine.
Zhang M; Ballard ME; Unger LV; Haupt A; Gross G; Decker MW; Drescher KU; Rueter LE
Behav Brain Res; 2007 Aug; 182(1):1-11. PubMed ID: 17570538
[TBL] [Abstract][Full Text] [Related]
17. A vehicle injection into the right core of the nucleus accumbens both reverses the region-specificity and alters the type of contralateral turning elicited by unilateral stimulation of dopamine D2/D3 and D1 receptors in the left core of the nucleus accumbens.
Ikeda H; Kotani A; Koshikawa N; Cools AR
Eur J Pharmacol; 2007 Dec; 577(1-3):64-70. PubMed ID: 17884038
[TBL] [Abstract][Full Text] [Related]
18. Actions at sites other than D(3) receptors mediate the effects of BP897 on l-DOPA-induced hyperactivity in monoamine-depleted rats.
Visanji NP; Millan MJ; Brotchie JM
Exp Neurol; 2006 Nov; 202(1):85-92. PubMed ID: 16814282
[TBL] [Abstract][Full Text] [Related]
19. Dopamine D1 receptor coupling to Gs/olf and Gq in rat striatum and cortex: a scintillation proximity assay (SPA)/antibody-capture characterization of benzazepine agonists.
Mannoury la Cour C; Vidal S; Pasteau V; Cussac D; Millan MJ
Neuropharmacology; 2007 Mar; 52(3):1003-14. PubMed ID: 17178132
[TBL] [Abstract][Full Text] [Related]
20. Dose-dependent effects of the dopamine D1 receptor agonists A77636 or SKF81297 on spatial working memory in aged monkeys.
Cai JX; Arnsten AF
J Pharmacol Exp Ther; 1997 Oct; 283(1):183-9. PubMed ID: 9336323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]